These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38332554)

  • 21. Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients.
    Yoshihara K; Gao Y; Shiga H; Wada DR; Hisaoka M
    Clin Pharmacokinet; 2005; 44(12):1329-42. PubMed ID: 16372830
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus.
    Fediuk DJ; Zhou S; Dawra VK; Sahasrabudhe V; Sweeney K
    Clin Pharmacol Drug Dev; 2021 Jul; 10(7):696-706. PubMed ID: 33205593
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.
    Golabchifar AA; Rezaee S; Dinan NM; Kebriaeezadeh A; Rouini MR
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):527-39. PubMed ID: 26189007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
    King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
    J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
    Gong JQX; Suleiman AA; Menon R; Deng R; Mensing S; Salem AH
    J Clin Pharmacol; 2023 Aug; 63(8):950-960. PubMed ID: 37055934
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Population pharmacokinetics of itraconazole and its active metabolite hydroxy-itraconazole in paediatric cystic fibrosis and bone marrow transplant patients.
    Hennig S; Wainwright CE; Bell SC; Miller H; Friberg LE; Charles BG
    Clin Pharmacokinet; 2006; 45(11):1099-114. PubMed ID: 17048974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pooled population pharmacokinetic analysis of phase I, II and III studies of linifanib in cancer patients.
    Salem AH; Koenig D; Carlson D
    Clin Pharmacokinet; 2014 Apr; 53(4):347-59. PubMed ID: 24307488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
    Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
    Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Population pharmacokinetics of ABT-767 in BRCA1 or BRCA2 mutation carriers with advanced solid tumors or in subjects with high grade serous ovarian, primary peritoneal or fallopian tube cancer.
    Mittapalli RK; Nuthalapati S; Shepherd SP; Xiong H
    Cancer Chemother Pharmacol; 2017 Mar; 79(3):587-594. PubMed ID: 28247011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
    Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Population Pharmacokinetics of Tafenoquine, a Novel Antimalarial.
    Thakkar N; Green JA; Koh GCKW; Duparc S; Tenero D; Goyal N
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30201820
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic Characteristics of Tofacitinib in Adult Patients With Moderate to Severe Chronic Plaque Psoriasis.
    Ma G; Xie R; Strober B; Langley R; Ito K; Krishnaswami S; Wolk R; Valdez H; Rottinghaus S; Tallman A; Gupta P
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):587-596. PubMed ID: 29856518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes.
    Dostalek M; Sam WJ; Paryani KR; Macwan JS; Gohh RY; Akhlaghi F
    Clin Pharmacokinet; 2012 Sep; 51(9):591-606. PubMed ID: 22775412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I-III Clinical Trials.
    Suleiman AA; Minocha M; Khatri A; Pang Y; Othman AA
    Clin Pharmacokinet; 2019 Oct; 58(10):1309-1321. PubMed ID: 31054118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia.
    Ogasawara K; Zhou S; Krishna G; Palmisano M; Li Y
    Cancer Chemother Pharmacol; 2019 Oct; 84(4):891-898. PubMed ID: 31444617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Population Pharmacokinetics of the BTK Inhibitor Acalabrutinib and its Active Metabolite in Healthy Volunteers and Patients with B-Cell Malignancies.
    Edlund H; Lee SK; Andrew MA; Slatter JG; Aksenov S; Al-Huniti N
    Clin Pharmacokinet; 2019 May; 58(5):659-672. PubMed ID: 30556110
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of moxifloxacin and its concentration-QT interval relationship modeling in Chinese healthy volunteers.
    Xu FY; Huang JH; He YC; Liang LY; Li LJ; Yang J; Yin F; Xu L; Zheng QS; Wang K
    Acta Pharmacol Sin; 2017 Nov; 38(11):1580-1588. PubMed ID: 28713157
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic modeling of idelalisib, a novel PI3Kδ inhibitor, in healthy subjects and patients with hematologic malignancies.
    Jin F; Gao Y; Zhou H; Fang L; Li X; Ramanathan S
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):89-98. PubMed ID: 26645408
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics analysis of guselkumab in healthy subjects and patients with psoriatic arthritis, plaque psoriasis and palmoplantar pustulosis.
    Tran L; Yao Z; Xu Z; Vermeulen A
    Br J Clin Pharmacol; 2022 Oct; 88(10):4481-4493. PubMed ID: 35470450
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.